This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2018 Nov 6;6(Suppl 1):114.

doi: 10.1186/s40425-018-0422-y.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018

No authors listed

PMID: 30400835
PMCID: PMC6220480
DOI: 10.1186/s40425-018-0422-y

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018

No authors listed. J Immunother Cancer. 2018.

. 2018 Nov 6;6(Suppl 1):114.

doi: 10.1186/s40425-018-0422-y.

PMID: 30400835
PMCID: PMC6220480
DOI: 10.1186/s40425-018-0422-y

Erratum in

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P. Berry S, et al. J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y. J Immunother Cancer. 2019. PMID: 30760319 Free PMC article.

No abstract available

PubMed Disclaimer

Figures

Fig. 1 (abstract P3). — Fig. 1 (abstract P3).
See text for description.

Fig. 2 (abstract P3). — Fig. 2 (abstract P3).
See text for description.

Fig. 1 (abstract P5). — Fig. 1 (abstract P5).
Anti-CD38 immunotherapy kills Treg and Breg

Fig. 1 (abstract P6). — Fig. 1 (abstract P6).
Anti-CD38 immunotherapy kills Treg and Breg

Fig. 1 (abstract P8). — Fig. 1 (abstract P8).
T Cell Polyfunctional Strength Enhanced by BiTEs

Fig. 1 (abstract P10). — Fig. 1 (abstract P10).
See text for description.

Fig. 2 (abstract P10). — Fig. 2 (abstract P10).
See text for description.

Fig. 1 (abstract P21). — Fig. 1 (abstract P21).
See text for description.

Image 1 (abstract P34). — Image 1 (abstract P34).
See text for description.

Image 2 (abstract P34). — Image 2 (abstract P34).
See text for description.

Image 3 (abstract P34). — Image 3 (abstract P34).
See text for description.

Fig. 1 (abstract P37). — Fig. 1 (abstract P37).
See text for description.

Fig. 2 (abstract P37). — Fig. 2 (abstract P37).
See text for description.

Fig. 1 (abstract P47). — Fig. 1 (abstract P47).
ELispot immune response in study subjects

Fig. 1 (abstract P64). — Fig. 1 (abstract P64).
See text for description.

Fig. 1 (abstract P66). — Fig. 1 (abstract P66).
See text for description.

Fig. 1 (abstract P71). — Fig. 1 (abstract P71).
See text for description.

Fig. 2 (abstract P71). — Fig. 2 (abstract P71).
See text for description.

Fig. 1 (abstract P79). — Fig. 1 (abstract P79).
See text for description.

Fig. 2 (abstract P79). — Fig. 2 (abstract P79).
See text for description.

Fig. 3 (abstract P79). — Fig. 3 (abstract P79).
See text for description.

Fig. 4 (abstract P79). — Fig. 4 (abstract P79).
See text for description.

Fig. 5 (abstract P79). — Fig. 5 (abstract P79).
See text for description.

Fig. 6 (abstract P79). — Fig. 6 (abstract P79).
See text for description.

Chart 1 (abstract P79). — Chart 1 (abstract P79).
See text for description.

Fig. 1 (abstract P80). — Fig. 1 (abstract P80).
Assay biochemistry

Fig. 2 (abstract P80). — Fig. 2 (abstract P80).
Gating strategy

Fig. 3 (abstract P80). — Fig. 3 (abstract P80).
High content readout

Fig. 1 (abstract P104). — Fig. 1 (abstract P104).
Radiomic expression and TIL density patterns

Fig. 1 (abstract P106). — Fig. 1 (abstract P106).
Spatial distribution of cells within tumor samples

Fig. 1 (abstract P109). — Fig. 1 (abstract P109).
See text for description.

Fig. 2 (abstract P109). — Fig. 2 (abstract P109).
See text for description.

Fig. 1 (abstract P110). — Fig. 1 (abstract P110).
See text for description.

Fig. 2 (abstract P110). — Fig. 2 (abstract P110).
See text for description.

Fig. 1 (abstract P113). — Fig. 1 (abstract P113).
Digital spatial profiling of AML

Fig. 1 (abstract P117). — Fig. 1 (abstract P117).
See text for description.

Fig. 1 (abstract P124). — Fig. 1 (abstract P124).
Multichannel immunofluorescence for CD8 and Batf-3

Fig. 1 (abstract P145). — Fig. 1 (abstract P145).
IDO1 feedback regulation network

Fig. 2 (abstract P145). — Fig. 2 (abstract P145).
Key factors in IDO1 feedback regulation

Fig. 1 (abstract P159). — Fig. 1 (abstract P159).
See text for description.

Fig. 2 (abstract P159). — Fig. 2 (abstract P159).
See text for description.

Fig. 3 (abstract P159). — Fig. 3 (abstract P159).
See text for description.

Fig. 1 (abstract P168). — Fig. 1 (abstract P168).
Inhibitory marker and chemokine

Fig. 2 (abstract P168). — Fig. 2 (abstract P168).
Inhibitory marker and chemokine

Fig. 1 (abstract P187). — Fig. 1 (abstract P187).
See text for description.

Fig. 2 (abstract P187). — Fig. 2 (abstract P187).
See text for description.

Fig. 3 (abstract P187). — Fig. 3 (abstract P187).
See text for description.

Fig. 1 (abstract P188). — Fig. 1 (abstract P188).
See text for description.

Fig. 1 (abstract P192). — Fig. 1 (abstract P192).
Pathology of stomach and duodenum pre vedolizumab

Fig. 2 (abstract P192). — Fig. 2 (abstract P192).
Pathology of stomach and duodenum post vedolizumab

Fig. 1 (abstract P194). — Fig. 1 (abstract P194).
See text for description.

Fig. 2 (abstract P194). — Fig. 2 (abstract P194).
See text for description.

Fig. 3 (abstract P194). — Fig. 3 (abstract P194).
See text for description.

Fig. 4 (abstract P194). — Fig. 4 (abstract P194).
See text for description.

Fig. 5 (abstract P194). — Fig. 5 (abstract P194).
See text for description.

Fig. 6 (abstract P194). — Fig. 6 (abstract P194).
See text for description.

Fig. 7 (abstract P194). — Fig. 7 (abstract P194).
See text for description.

Fig. 8 (abstract P194). — Fig. 8 (abstract P194).
See text for description.

Fig. 9 (abstract P194). — Fig. 9 (abstract P194).
See text for description.

Fig. 1 (abstract P196). — Fig. 1 (abstract P196).
Effect of supplements on antigen specific T cells

Fig. 1 (abstract P200). — Fig. 1 (abstract P200).
See text for description.

Fig. 2 (abstract P200). — Fig. 2 (abstract P200).
See text for description.

Fig. 1 (abstract P201). — Fig. 1 (abstract P201).
See text for description.

Fig. 1 (abstract P212). — Fig. 1 (abstract P212).
See text for description.

Fig. 1 (abstract P216). — Fig. 1 (abstract P216).
See text for description.

Fig. 1 (abstract P217). — Fig. 1 (abstract P217).
See text for description.

Fig. 1 (abstract P236). — Fig. 1 (abstract P236).
See text for description.

Fig. 1 (abstract P239). — Fig. 1 (abstract P239).
See text for description.

Fig. 2 (abstract P239). — Fig. 2 (abstract P239).
See text for description.

Fig. 3 (abstract P239). — Fig. 3 (abstract P239).
See text for description.

Fig. 4 (abstract P239). — Fig. 4 (abstract P239).
See text for description.

Fig. 5 (abstract P239). — Fig. 5 (abstract P239).
See text for description.

Fig. 6 (abstract P239). — Fig. 6 (abstract P239).
See text for description.

Fig. 1 (abstract P240). — Fig. 1 (abstract P240).
CITADEL OS estimated by Kaplan-Meier method (n=15)

Fig. 1 (abstract P248). — Fig. 1 (abstract P248).
See text for description.

Fig. 1 (abstract P251). — Fig. 1 (abstract P251).
Characterization TILs derived from pancreatic tumor

Fig. 1 (abstract P252). — Fig. 1 (abstract P252).
Immunohistochemical analysis of NYESO-1

Fig. 2 (abstract P252). — Fig. 2 (abstract P252).
Characterization of TILs derived pancreatic tumor

Fig. 1 (abstract P253). — Fig. 1 (abstract P253).
TIB repertoire in early-cultured TILs

Fig. 1 (abstract P257). — Fig. 1 (abstract P257).
See text for description.

Fig. 1 (abstract P260). — Fig. 1 (abstract P260).
See text for description.

Fig. 2 (abstract P260). — Fig. 2 (abstract P260).
See text for description.

Fig. 3 (abstract P260). — Fig. 3 (abstract P260).
See text for description.

Fig. 4 (abstract P260). — Fig. 4 (abstract P260).
See text for description.

Fig. 1 (abstract P266). — Fig. 1 (abstract P266).
Polyfunctional strength index (PSI) of CD4+ cells

Fig. 2 (abstract P266). — Fig. 2 (abstract P266).
TMVs generated from PDX tumor decorated IL-12 B7-1

Fig. 1 (abstract P287). — Fig. 1 (abstract P287).
Swimmer's plot

Fig. 1 (abstract P292). — Fig. 1 (abstract P292).
See text for description.

Fig. 1 (abstract P307). — Fig. 1 (abstract P307).
See text for description.

Fig. 1 (abstract P316). — Fig. 1 (abstract P316).
See text for description.

Fig. 1 (abstract P330). — Fig. 1 (abstract P330).
Trial Schematic

Fig. 1 (abstract P332). — Fig. 1 (abstract P332).
See text for description.

Fig. 1 (abstract P333). — Fig. 1 (abstract P333).
See text for description.

Fig. 1 (abstract P338). — Fig. 1 (abstract P338).
Enoblituzumab binds B7-H3 with high affinity and specificity

Fig. 2 (abstract P338). — Fig. 2 (abstract P338).
Enoblituzumab Treated Prostatectomy CD8+ T Cell Infiltrates

Fig. 3 (abstract P338). — Fig. 3 (abstract P338).
CD8+ T Cell Quantitation in Enoblituzumab-treated Prostates

Fig. 1 (abstract P339). — Fig. 1 (abstract P339).
See text for description.

Fig. 1 (abstract P344). — Fig. 1 (abstract P344).
See text for description.

Fig. 2 (abstract P344). — Fig. 2 (abstract P344).
See text for description.

Fig. 3 (abstract P344). — Fig. 3 (abstract P344).
See text for description.

Fig. 4 (abstract P344). — Fig. 4 (abstract P344).
See text for description.

Fig. 5 (abstract P344). — Fig. 5 (abstract P344).
See text for description.

Fig. 1 (abstract P354). — Fig. 1 (abstract P354).
See text for description.

Fig. 1 (abstract P359). — Fig. 1 (abstract P359).
See text for description.

Fig. 1 (abstract P374). — Fig. 1 (abstract P374).
See text for description.

Fig. 1 (abstract P376). — Fig. 1 (abstract P376).
VIPhyb+anti-PD-1 in melanoma models

Fig. 2 (abstract P376). — Fig. 2 (abstract P376).
VIPhyb+anti-PD-1 in pancreatic cancer models

Fig. 3 (abstract P376). — Fig. 3 (abstract P376).
VIPhyb+anti-PD1 increases CD4+ PD1+ T cells

Fig. 4 (abstract P376). — Fig. 4 (abstract P376).
VIPhyb+ anti-PD-1 increases CD8+ T cells in tumor

Fig. 1 (abstract P382). — Fig. 1 (abstract P382).
tSNE T cell analysis: matching Blood and TILs

Fig. 2 (abstract P382). — Fig. 2 (abstract P382).
tSNE overlay using machine-learning approaches

Fig. 1 (abstract P387). — Fig. 1 (abstract P387).
TACTI-002 trial design

Fig. 1 (abstract P390). — Fig. 1 (abstract P390).
See text for description.

Fig. 2 (abstract P390). — Fig. 2 (abstract P390).
See text for description.

See this image and copyright information in PMC

Similar articles

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.
[No authors listed] [No authors listed] J Immunother Cancer. 2018 Nov 6;6(Suppl 1):115. doi: 10.1186/s40425-018-0423-x. J Immunother Cancer. 2018. PMID: 30400822 Free PMC article. No abstract available.
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019.
[No authors listed] [No authors listed] J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282. doi: 10.1186/s40425-019-0763-1. J Immunother Cancer. 2019. PMID: 31694725 Free PMC article. No abstract available.
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2 : National Harbor, MD, USA. 10 November 2019.
[No authors listed] [No authors listed] J Immunother Cancer. 2019 Nov 6;7(Suppl 1):283. doi: 10.1186/s40425-019-0764-0. J Immunother Cancer. 2019. PMID: 31694708 Free PMC article. No abstract available.
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
Gulley JL, Repasky EA, Wood LS, Butterfield LH. Gulley JL, et al. J Immunother Cancer. 2017 Jul 18;5(1):55. doi: 10.1186/s40425-017-0262-1. J Immunother Cancer. 2017. PMID: 28716068 Free PMC article. Review.
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31^stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. Adusumilli PS, et al. J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. J Immunother Cancer. 2017. PMID: 28649381 Free PMC article. Review.

See all similar articles

Cited by

Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis.
Zou H, Lei Q, Yan X, Lai Y, Ung COL, Hu H. Zou H, et al. Cancers (Basel). 2022 Dec 30;15(1):260. doi: 10.3390/cancers15010260. Cancers (Basel). 2022. PMID: 36612256 Free PMC article. Review.
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.
Müller D. Müller D. BioDrugs. 2023 Jan;37(1):21-33. doi: 10.1007/s40259-022-00573-3. Epub 2022 Dec 26. BioDrugs. 2023. PMID: 36571696 Free PMC article. Review.
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
Liu C, Zhang G, Xiang K, Kim Y, Lavoie RR, Lucien F, Wen T. Liu C, et al. Cancer Immunol Immunother. 2022 Jul;71(7):1549-1567. doi: 10.1007/s00262-021-03097-x. Epub 2021 Nov 5. Cancer Immunol Immunother. 2022. PMID: 34739560 Free PMC article. Review.
Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Lee SW, Lee HY, Kang SW, Kim MJ, Lee YJ, Sung CO, Kim YM. Lee SW, et al. Int J Mol Sci. 2021 Sep 6;22(17):9638. doi: 10.3390/ijms22179638. Int J Mol Sci. 2021. PMID: 34502561 Free PMC article.
STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
Rossi M, Carboni S, Di Berardino-Besson W, Riva E, Santiago-Raber ML, Belnoue E, Derouazi M. Rossi M, et al. Front Immunol. 2021 Jul 1;12:695056. doi: 10.3389/fimmu.2021.695056. eCollection 2021. Front Immunol. 2021. PMID: 34276686 Free PMC article.

See all "Cited by" articles

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database